JP2022525754A5 - - Google Patents

Info

Publication number
JP2022525754A5
JP2022525754A5 JP2021555430A JP2021555430A JP2022525754A5 JP 2022525754 A5 JP2022525754 A5 JP 2022525754A5 JP 2021555430 A JP2021555430 A JP 2021555430A JP 2021555430 A JP2021555430 A JP 2021555430A JP 2022525754 A5 JP2022525754 A5 JP 2022525754A5
Authority
JP
Japan
Prior art keywords
sequence
seq
polypeptide
adjacent
trka
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021555430A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525754A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023846 external-priority patent/WO2020191289A1/en
Publication of JP2022525754A publication Critical patent/JP2022525754A/ja
Publication of JP2022525754A5 publication Critical patent/JP2022525754A5/ja
Pending legal-status Critical Current

Links

JP2021555430A 2019-03-20 2020-03-20 医療用ｎｇｆアンタゴニスト Pending JP2022525754A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962821438P 2019-03-20 2019-03-20
US62/821,438 2019-03-20
PCT/US2020/023846 WO2020191289A1 (en) 2019-03-20 2020-03-20 Ngf antagonists for medical use

Publications (2)

Publication Number Publication Date
JP2022525754A JP2022525754A (ja) 2022-05-19
JP2022525754A5 true JP2022525754A5 (https=) 2023-03-16

Family

ID=72521232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021555430A Pending JP2022525754A (ja) 2019-03-20 2020-03-20 医療用ｎｇｆアンタゴニスト

Country Status (10)

Country Link
US (1) US20220169740A1 (https=)
EP (1) EP3941933A4 (https=)
JP (1) JP2022525754A (https=)
KR (1) KR20220066002A (https=)
CN (1) CN113840831A (https=)
AU (1) AU2020240120A1 (https=)
BR (1) BR112021018156A2 (https=)
CA (1) CA3133104A1 (https=)
MX (1) MX2021011335A (https=)
WO (1) WO2020191289A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12297272B2 (en) 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
CN120904316A (zh) * 2018-12-27 2025-11-07 伊兰科美国公司 兽用IgG Fc变体
CN115996949A (zh) * 2020-04-17 2023-04-21 硕腾服务有限责任公司 犬抗体变异体
KR20230005875A (ko) * 2020-04-22 2023-01-10 킨드레드 바이오사이언시스, 인코포레이티드 수의학 용도를 위한 장시간-작용성 항-il31 항체
AU2022329459A1 (en) 2021-08-20 2024-02-29 Intervet International B.V. Antibodies and igg fusion proteins with an extended half-life
EP4419547A1 (en) * 2021-10-21 2024-08-28 Petmedix Ltd. Proteins comprising the extracellular domain of p75ntr
US11608371B1 (en) 2021-10-21 2023-03-21 Petmedix Ltd Therapeutic molecules
KR20250141832A (ko) * 2023-02-09 2025-09-29 펫메딕스 리미티드 P75 뉴로트로핀 수용체(p75ntr)의 세포외 도메인 변이체를 포함하는 치료 분자

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807781D0 (en) * 1998-04-09 1998-06-10 Univ Bristol Therapeutic agent
GB0020504D0 (en) * 2000-08-18 2000-10-11 Univ Bristol Therapeutic method
MX370489B (es) * 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
WO2007059574A1 (en) * 2005-11-23 2007-05-31 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
US7342146B2 (en) * 2006-01-11 2008-03-11 Industrial Technology Research Institute Neurodegenerative non-human transgenic mammal expressing TrkA fusion protein
CA2754408A1 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
WO2014093387A1 (en) * 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
GB201308738D0 (en) * 2013-05-15 2013-06-26 Polytherics Ltd Novel polymer conjugates
JPWO2015064621A1 (ja) * 2013-10-29 2017-03-09 公益財団法人がん研究会 新規融合体及びその検出法
WO2016035052A1 (en) * 2014-09-05 2016-03-10 Nvip Pty Ltd Anti-nerve growth factor antibodies for treating itching
US9517238B2 (en) * 2014-11-07 2016-12-13 Children's Hospital Medical Center Compositions and methods for treating allergic inflammation through inhibition of NTRK1
US12297272B2 (en) * 2017-08-15 2025-05-13 Eianco US inc. IgG Fc variants for veterinary use
CN120904316A (zh) * 2018-12-27 2025-11-07 伊兰科美国公司 兽用IgG Fc变体

Similar Documents

Publication Publication Date Title
JP2022525754A5 (https=)
JP4255618B2 (ja) 単鎖二官能性糖タンパク質ホルモン
JP5952847B2 (ja) 成長因子と結合する融合タンパク質
AU2018201132B2 (en) BMP-ALK3 antagonists and uses for promoting bone growth
JP6250714B2 (ja) Ｆｇｆ２１突然変異体及びその使用
JP7776461B2 (ja) 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
KR102564079B1 (ko) 진행성 골화성 섬유이형성증의 치료
US20190248858A1 (en) Novel feline erythropoietin receptor agonists
US20250376512A1 (en) Modified product of fc domain of antibody
JPH07508178A (ja) レセプター活性化
JP2006506041A (ja) Ｏｘ４０ｒ結合剤
JP7821741B2 (ja) 動物用のｉｌ４／ｉｌ１３受容体分子
US20220169740A1 (en) NGF Antagonists for Medical Use
WO2021247675A1 (en) Coronavirus-binding agents and uses thereof
US20220025005A1 (en) Erythropoietin Analogs For Veterinary Use
NZ728020A (en) Anti-il4-il 13 bispecific antibodies
BR112019025563A2 (pt) Eritropoietina e análogos para uso veterinário
TW201902920A (zh) 重組robo2蛋白、組合物、方法及其用途
RU2021130369A (ru) Антагонисты ngf для медицинского использования
CN116769015A (zh) 一种牛IgG Fc受体boFcγRIII的线性配体结合表位
MX2008009289A (es) Peptidos de enlace al factor de crecimiento de fibroblasto 2 y usos de los mismos.
EA039118B1 (ru) Способ лечения прогрессирующей оссифицирующей фибродисплазии
HK1125299A (zh) 用d114拮抗剂抑制肿瘤生长的治疗方法